Business update on LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) Nov 16, 2026 at 8:00 AM EST Listen to webcast Supporting Materials Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 in PKP2 Arrhythmogenic Cardiomyopathy 1.3 MB
Interim Clinical Data from the Phase 1/2 HEROIC-PKP2 Trial of LX2020 in PKP2 Arrhythmogenic Cardiomyopathy 1.3 MB